Lupin has provided an update on its acquisition timeline for Amsterdam-based VISUfarma BV, indicating the transaction is now expected to close by February 28, 2026, subject to certain closing conditions. The pharmaceutical company had originally indicated the acquisition would be completed by the end of calendar year 2025. This development comes alongside the company's recent strategic partnership announcement for GLP-1 drug commercialization in India.

VISUfarma Acquisition Update

The company recalled that Nanomi BV, its wholly-owned subsidiary, had entered into a definitive agreement on September 29, 2025, to acquire the entire share capital of VISUfarma BV. The acquisition represents part of Lupin's broader expansion strategy, though specific financial terms and strategic rationale for the VISUfarma deal have not been disclosed.

GLP-1 Drug Partnership Reinforced

Simultaneously, Lupin has reaffirmed its exclusive licensing, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. This strategic partnership strengthens Lupin's diabetes portfolio while expanding its presence in the obesity treatment segment for the Indian market.

Bofanglutide injection is designed for adults with type 2 diabetes and assists in weight management for overweight or obese individuals. As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that weight loss results are comparable to or better than existing GLP-1 alternatives while offering enhanced convenience through reduced injection frequency.

Market Opportunity and Health Impact

The GLP-1 partnership addresses significant health challenges in India, where obesity is anticipated to develop into a major health crisis. The market opportunity remains substantial, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes already affects approximately 90 million adults in the country, representing an epidemic-level health concern.

Current Stock Performance

Shares of Lupin ended at ₹2,080.40, declining by ₹1.70 or 0.08% during the latest trading session. The stock has faced broader challenges with a year-to-date decline of 12.00%, though the strategic partnerships in high-growth therapeutic areas are expected to draw continued investor attention.

Lupin Limited , a global pharmaceutical leader, has announced a significant move to strengthen its presence in the European ophthalmology market. The company's wholly-owned subsidiary, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a Netherlands-based specialty pharmaceutical company, for an enterprise value of €190 million.

Revised Transaction Timeline

In a recent regulatory filing, Lupin has provided an update on the acquisition timeline. The company has informed stock exchanges that the proposed transaction, originally expected to be completed by the end of 2025, is currently in progress and is now expected to be completed by February 28, 2026, subject to certain closing conditions.

Strategic Expansion into European Ophthalmology

The acquisition of VISUfarma aligns with Lupin's strategy to expand its European business and advance its global specialty franchise in ophthalmology. VISUfarma, founded in 2016, has established a strong presence across major European countries, including Italy, the UK, Spain, Germany, and France.

VISUfarma's Portfolio and Performance

VISUfarma offers a comprehensive portfolio of over 60 branded ophthalmology products, covering key areas such as dry eye treatments, glaucoma care, eyelid hygiene, blepharitis management, retinal health solutions, and specialized nutraceuticals.

Regulatory Approvals and Current Status

The acquisition requires approval from national authorities for foreign direct investment in Germany and notification in Spain. Lupin will finance the acquisition through existing cash on its balance sheet. The transaction, valued at €190 million enterprise value, is expected to be accretive to Lupin's growth and margin profile.

Market Expansion Opportunities

This strategic move will provide Lupin with direct presence in major European markets, opportunities for business diversification, and a platform to accelerate expansion into the specialty ophthalmology segment across regions. The global ophthalmology market, currently valued at approximately €28 billion, is experiencing significant growth driven by an aging global population, increasing incidence of diabetes-related eye complications, and growing awareness of preventive care.